Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 14, 2022
Discovery & Translation

Codiak’s pan beta-coronavirus vaccine; plus CNS-penetrating AAV9 variants and more

BioCentury’s roundup of translational news
BioCentury | Jun 25, 2022
Discovery & Translation

Expanding the CAR T cell toolbox

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Immune system biomarkers take center stage among emerging targets at ASH 2019
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

Parker Institute gathers its investigators’ cell therapy technologies into cancer cell therapy newco ArsenalBio
Items per page:
1 - 4 of 4